

Disparate Prednisone Starting Dosages for Systemic Corticosteroid-Naïve Veterans With Active Sarcoidosis

Nadera J. Sweiss, MD^a; Zane Z. Elfessi, PharmD^a; Mandeep K. Sidhu, MD, MB^{a,b}; Israel Rubinstein, MD^{a,c}

Background: Sarcoidosis is a multiorgan granulomatous disorder of unknown etiology. Clinical manifestations vary and depend, in part, on the extent and severity of organ involvement. Clinical practice guidelines recommend 20 to 40 mg prednisone daily as first-line pharmacotherapy for systemic corticosteroid-naïve patients with active sarcoidosis. This study sought to determine whether initial dosages were guideline adherent.

Methods: Records were retrospectively reviewed for patients diagnosed with sarcoidosis who were naïve to systemic corticosteroids and received initial prednisone dosages between 2014 and 2023 at the Jesse Brown Department of Veterans Affairs Medical Center. Patient demographics,

medical specialty of the prescriber, and daily starting dosage were tabulated.

Results: Sixty-eight patients were identified; most were Black (n = 52, 76%) and male (n = 62, 91%), with a mean (SD) age of 63 (11) years. Pulmonologists prescribed initial prednisone dosages in the 20 to 40 mg daily range (median, 35 mg). Other specialists, including primary care practitioners, often prescribed 20 mg (median, 17.5 mg; $P < .05$) initial dosages.

Conclusions: Initial prednisone dosages varied between pulmonologists and nonpulmonologists for systemic corticosteroid-naïve patients with active sarcoidosis. However, this study did not determine reasons for this phenomenon, nor its impact on long-term patient outcomes.

Author affiliations can be found at the end of this article.

Correspondence:

Nadera Sweiss
(nsweiss@uic.edu)

Fed Pract. 2025;42(7).
Published online July 17.
doi:10.12788/fp.0605

Sarcoidosis is a multiorgan granulomatous disorder of unknown etiology that impacts many US veterans.¹ At diagnosis, clinical manifestations vary and partially depend on the extent and severity of organ involvement, particularly of the lungs, heart, and eyes.^{2,3} Sarcoidosis may lead to progressive organ dysfunction, long-term disability, and death.¹⁻³ Clinical practice guidelines recommend prednisone 20 to 40 mg daily or equivalent-prednisone dose followed by a slow tapering, as first-line pharmacotherapy for patients with active sarcoidosis who are naïve to systemic corticosteroids.²⁻⁴

Use of prolonged, high-dosage prednisone (> 40 mg daily) is discouraged due to a high risk of corticosteroid-related adverse events and associated health care costs.^{5,6} Research suggests that initial lower prednisone dosage (< 20 mg daily) may be effective in systemic corticosteroid-naïve patients with active sarcoidosis.³

Adherence to this regimen by specialists (eg, pulmonologists, dermatologists, ophthalmologists, rheumatologists, and cardiologists) has not been established. This study sought to determine the starting dosages for prednisone prescribed at the Jesse Brown Department of Veterans Affairs Medical Center (JBVAMC) to patients

with active sarcoidosis who were systemic corticosteroid-naïve.

METHODS

Patient data were reviewed from the Computerized Patient Record System (CPRS) for individuals diagnosed with sarcoidosis who were corticosteroid-naïve and prescribed initial prednisone dosages by health care practitioners (HCPs) from several specialties between 2014 and 2023 at JBVAMC. This 200-bed acute care facility serves about 62,000 veterans who live in Illinois or Indiana. JBVAMC is affiliated with the University of Illinois College of Medicine at Chicago, Northwestern University Feinberg School of Medicine, and the University of Chicago Pritzker School of Medicine; many JBVAMC HCPs hold academic appointments with these medical schools.

Patient demographics, prescriber specialty, and daily starting dosage were recorded. The decision to initiate prednisone therapy and its dosage were at the discretion of HCPs who diagnosed active sarcoidosis based on compatible clinical and ancillary test findings as documented in CPRS.^{2-4,6-10} Statistical analyses were conducted using a *t* test, and a threshold of $P < .05$ was considered statistically significant. This study was reviewed and

TABLE 1. Baseline Patient Characteristics (N = 68)

Characteristic	Cardiology	Dermatology	Neurology	Ophthalmology	Pulmonology	Rheumatology	Primary care
No.	1	6	1	6	40	5	9
Age, mean (SD), y	78	63 (3)	46	67 (8)	62 (10)	73	60 (16)
Male sex, No.	1	5	1	5	37	5	8
Race, No. (%)							
African American	1	5	0	4	35	3	4
White	0	0	0	1	3	1	3
Hispanic, Asian, or Pacific Islander	0	1	1	1	2	1	2
Body mass index, mean (SD)	25	36 (6)	27	29 (5)	30 (6)	27 (6)	28 (6)

determined to be exempt by the JBVAMC institutional review board.

RESULTS

Sixty-eight patients who were systemic corticosteroid-naïve and had sarcoidosis were prescribed prednisone by HCPs at JBVAMC. Fifty-two were Black (76%), 62 were male (91%), and 53 were current or former smokers (78%). The mean (SD) age was 63 (11) years (Table 1). Forty patients (59%) had lung involvement, 6 had eye (9%), 6 had skin (9%), and 5 had musculoskeletal system (7%) involvement.

Pulmonologists predominantly prescribed initial dosage of 20 mg to 40 mg (median, 35 mg daily) (Figure). Other HCPs, including primary care, tended to prescribe prednisone < 20 mg (median, 17.5 mg; $P < .05$) (Table 2). The highest initial prednisone dosage was 80 mg daily, prescribed by a neurologist for a patient with neurosarcoidosis. Voortman et al recommend 20 to 40 mg prednisone daily for neurosarcoidosis.⁷ Both groups, pulmonologists and nonpulmonologists, had no significant differences in patient characteristics.

DISCUSSION

Disparate prescription patterns of initial prednisone dosages were observed between pulmonologists and nonpulmonologists treating systemic corticosteroid-naïve patients with active sarcoidosis at JBVAMC. This study did not determine the underlying reasons for this phenomenon, nor its impact on patient outcomes.

Clinical practice guidelines have not been independently validated for each organ af-




FIGURE. Prednisone starting dosages for systemic corticosteroid-naïve patients with active sarcoidosis prescribed by pulmonologists, 2014 to 2023.

ected by sarcoidosis.^{2-4,6-10} Variations in clinical practice for other specialties may account for the variable prednisone starting dosage selection. For example, among 6 patients with active ocular sarcoidosis treated by ophthalmologists, 4 were prescribed an initial prednisone dosage of ≤ 10 mg daily. The American Academy of Ophthalmology recommends an initial short-term course of prednisone at 1 to 1.5 mg/kg daily, tapered down to the lowest effective dosage.¹⁰

Limitations

This study used a small, single-center predominantly older Black male patient cohort. The generalizability of these observations is unknown. A larger, multicenter prospective study is warranted to further evaluate these initial observations.

CONCLUSIONS

HCPs treating patients who are systemic corticosteroid-naïve with active sarcoidosis for whom prednisone is indicated should adhere to current clinical practice guide-

TABLE 2. Oral Corticosteroids Prescribed by Nonpulmonologist Specialty (N = 68)^a

Dosage, mg	Cardiology	Dermatology	Neurology	Ophthalmology	Primary care	Rheumatology
5	0	0	0	3	3	1
7.5	0	0	0	0	1	0
10	0	0	0	1	0	2
15	0	1	0	1	0	0
20	0	0	0	0	2	1
30	1	0	0	0	1	1
35	0	0	0	0	0	0
40	0	3	0	0	2	0
55	0	0	0	0	0	0
60	0	1	0	1	0	0
80	0	0	1	0	0	0

lines by prescribing prednisone in the 20 to 40 mg daily range.

Acknowledgments

This material results from work supported with resources and the use of facilities at the Jesse Brown Department of Veterans Affairs Medical Center, Chicago, Illinois. The authors thank Michael Nissen, ELS, for editorial support in the revision of this manuscript. This support was funded by the University of Illinois Chicago.

Author affiliations

^aUniversity of Illinois Chicago

^bUniversity of Jordan, Amman

^cAlbany Medical College, New York

^dJesse Brown Department of Veterans Affairs Medical Center, Chicago, Illinois

Author disclosures

The authors report no actual or potential conflicts of interest in regard to this article.

Disclaimer

The opinions expressed herein are those of the authors and do not necessarily reflect those of *Federal Practitioner*, Frontline Medical Communications Inc., the official position or policy of the Defense Health Agency, US Department of Defense, the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

References

- Seedahmed MI, Baugh AD, Albair MT, et al. Epidemiology of sarcoidosis in U.S. veterans from 2003 to 2019. *Ann Am Thorac Soc*. 2023;20(6):797-806. doi:10.1513/AnnalsATS.202206-515OC
- Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079. doi:10.1183/13993003.04079-2020
- Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. *Eur Respir Rev*. 2020;29(155):190146. doi:10.1183/16000617.0146-2019
- Kwon S, Judson MA. Clinical pharmacology in sarcoidosis: how to use and monitor sarcoidosis medications. *J Clin Med*. 2024;13(5):1250. doi:10.3390/jcm13051250
- Rice JB, White AG, Johnson M, et al. Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. *Curr Med Res Opin*. 2018;34(8):1519-1527. doi:10.1080/03007995.2018.1474090
- Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, et al. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. *J Med Econ*. 2018;21(9):846-852. doi:10.1080/13696998.2018.1474750
- Voortman M, Drent M, Baughman RP. Management of neurosarcoidosis: a clinical challenge. *Curr Opin Neurol*. 2019;32(3):475-483. doi:10.1097/WCO.0000000000000684
- Cheng RK, Kittleson MM, Beavers CJ, et al. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. *Circulation*. 2024;149(21):e1197-e1216. doi:10.1161/CIR.0000000000001240
- Cohen E, Lheure C, Ingen-Housz-Oro S, et al. Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients. *Eur J Dermatol*. 2023;33(6):680-685. doi:10.1684/ejd.2023.4584
- American Academy of Ophthalmology. Ocular manifestations of sarcoidosis. EyeWiki. Accessed June 3, 2025. https://eyewiki.org/Ocular_Manifestations_of_Sarcoidosis